Exicure, Inc. (NASDAQ:XCUR) Shares Shorted: Short Interest Down 46.9% in September

Exicure, Inc. (NASDAQ:XCUR) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 37,561 shares, a decline of 46.9% from the September 15th total of 70,672 shares. Currently, 1.2% of the company’s shares are short sold. Based on an average daily volume of 18,763 shares, the short-interest ratio is presently 2.0 days.

Exicure Trading Up 5.5%

Shares of XCUR opened at $1.15 on Wednesday. The company has a 50-day moving average of $1.26 and a two-hundred day moving average of $2.29. Exicure has a one year low of $0.94 and a one year high of $9.48.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.42.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exicure in a report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Exicure presently has an average rating of “Sell”.

About Exicure

Exicure, Inc is a biotechnology company that historically focused on developing nucleic acid-based medicines. Its research was built around Spherical Nucleic Acid (SNA) technology, a platform designed to package and deliver short strands of genetic material into cells to influence disease-related biological pathways.

The company’s development programs included investigational treatments for oncology, inflammatory diseases and genetic disorders. Its most prominent candidates included cavrotolimod, an immunotherapy designed to activate the toll-like receptor 9 pathway, and earlier dermatology-focused programs intended to address conditions such as psoriasis and related inflammatory diseases.